Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a ...

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer, TROP2-directed Datroway.

AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) voluntarily, intended for datopotamab deruxtecan (Dato-DXd), to treat advanced ...

The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are important because many patients do not live long enough to receive a second-line cancer therapy. By Frank ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

AstraZeneca, Daiichi Sankyo win first U.S. approval for key cancer drug AstraZeneca has forecast peak annual sales of the drug, to be marketed as Datroway, at more than $5 billion Manage alerts ...

AstraZeneca And Daiichi Sankyo's Datroway Gets US Approval For Metastatic HR+ Breast Cancer January 20, 2025 — 02:23 am EST Written by RTTNews.com for RTTNews -> ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast ...

AstraZeneca, which is partnered with Daiichi Sankyo on the drug, has cited Dato-DXd as one of the products that will help it achieve its goal of nearly doubling its revenue to $80 billion by 2030 ...

AstraZeneca's Enhertu combo improved progression-free survival in HER2+ metastatic breast cancer in a Phase 3 trial, showing promising early results.

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a first-line breast cancer trial, the companies have scored again in another ...